Cancer-Killing Virus May Be The Answer For Patients With KRAS Mutated Tumors : RushPRNews - Newswire & Global Press Release Distribution

Bookmark and Share

Cancer-Killing Virus May Be The Answer For Patients With KRAS Mutated Tumors

July 28, 2009

Calgary, AB (RPRN) 7/28/2009--According to the American Cancer Society, about 150,000 Americans will be diagnosed with colorectal cancer in 2009.  These patients are widely treated with a drug regimen that includes a class of drugs called anti-EGFR monoclonal antibodies. The product labels on this class of drugs known as anti-EGFR monoclonal antibodies, specifically cetuximab (Erbitux®) and panitumumab (Vectibix®) have just been changed so that they will no longer be recommended for the treatment of patients with colorectal cancers having a specific mutation (KRAS).

Retrospective subset analysis of seven separate randomized trials in patients with colorectal cancers having KRAS mutations, noted a lack of benefit associated with these monoclonal antibodies. The percentage of study populations for which KRAS status was assessed range from 23 to 92%.
Patients can now be screened for EGFR and KRAS status, and patients with KRAS mutations will not be treated with therapies that are unlikely to provide benefit. Patients with just EGFR mutations or overexpression will now be treated with anti-EGFR antibodies with a higher certainty of response.  For patients with mutations in KRAS, the good news is that an alternative therapy is currently being developed for them. An oncolytic virus being developed by Oncolytics Biotech Inc. can kill cancer cells with this particular mutation and with EGFR mutations as well, and is already well-advanced into clinical trials in the U.S. and the U.K.

REOLYSIN, Oncolytics’ proprietary formulation of the reovirus, preferentially replicates in cancer cells that have an activated RAS pathway.  Approximately two-thirds of all cancers have an activated RAS pathway, including most metastatic disease.  A large number of mutations, including mutations in EGFR, Her2 or KRAS along the RAS pathway lead to RAS pathway activation.
REOLYSIN works by exploiting any mutation that leads to an activated RAS pathway. These mutations allow the virus to replicate inside tumor cells, producing thousands of copies of itself.  Eventually, the cancer cells die, releasing the virus particles, which in turn infect other cancer cells. To date, more than 280 patients with various forms of cancer have been treated with REOLYSIN in various trials in Canada, the U.S., and the U.K.  Side effects of oncolytic virus treatment are mild compared with those of chemotherapy or radiation. Some patients report a combination of mild, flu-like symptoms, which usually resolve rapidly.

While REOLYSIN is not yet available to the public, the Company has submitted a protocol to the U.S. FDA for a Phase III trial, the last step before applying for product approval.
Already underway is a U.S. Phase II clinical study using REOLYSIN in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with KRAS or EGFR-activated tumors.  Like colorectal cancer patients, those with mutant KRAS, or up to 20 per cent of the more than 180,000 patients diagnosed every year in the U.S. with NSCLC, do not derive benefit from EGFR-based therapies.

Together, KRAS mutated lung and colorectal cancers account for close to 100,000 newly diagnosed cases of cancer every year in the U.S.  KRAS mutated cancers are also found at high rates in leukemias and pancreatic cancers.  Advances in screening and treatment offer a prime example of the way personalized medicine can be used to tailor therapies to individuals with these cancers, possibly improving or extending life, while avoiding costly treatments that offer little to no benefit. For more information, log on to

Media contact: Janet Vasquez, The Investor Relations Group, 212-825-3210

About the author:

Janet Vasquez, Director of Corporate Communications

About IRG

We are The Investor Relations Group (IRG), a full-service corporate communications firm that provides investor relations and public relations services to nano-, micro- and small-cap companies providing them with the equivalent in-house services of a large-cap company.

Click here to see all news from this author/company

Filed Under: Health and Fitness, Lifestyle, PRESS RELEASE, FDA- Pharmaceutical news, SCIENCE

RUSH PR NEWS newswire and press release services at / AH Marketing

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.


Newborn Foundation Hosts Annual Awards Gala

SAINT PAUL, MN 10/21/16 · U.S. Senator Amy Klobuchar honored: More than $220,000 raised...

Beyoncé and Destiny's Child Documentary Set to Premiere in Houston

Houston, Texas USA 10/15/16 · Making a Child of Destiny: The Andretta Tillman...

Far East Hospitality named Best Employer 2016 by Aon Hewitt

Singapore 10/13/16 · - Far East Hospitality, Singapore’s leading operator of...

Attorney Scott Glovsky Launches Trial Lawyer Talk, A New Legal Podcast

Pasadena, CA 10/13/16 ·  – Award-winning California trial attorney Scott Glovsky has...

Pre-Owned Mercedes Cars that are Worth Buying

Toronto, Canada 10/08/16 · Every car lover dreams of buying a Mercedes...

TryMyKitchen goes global as the first and best dedicated marketplace for booking cooking classes

London, UK 10/07/16 · offers an unrivalled service for people wishing...

Jafme Inc.: New Job Search App Brings New Opportunities

New York 10/07/16 · Jafme Inc. unveiled new mobile app to assist...

Rainwater Sustainable Alternative To Drilling Wells And Hauling Water

CRAIK, SK 10/07/16 · Local Company Says Canadians Can Conserve Water and...

Visionup Strobe Glasses

Tokyo, Japan 10/06/16 · The world’s 1st Strobe Glasses for young athletes Visionup...

Quality Roofing Contractors in Melbourne

AUSTRALIA 10/06/16 · A roof is part of a building’s exterior...

Utilization of Water Treatment Plant

Ahmedabad, Gujarat 10/06/16 · Water, a characteristic and fundamental asset is without...

New Dodge RAM 1500 Has All the Qualities of Becoming A Reliable Pickup Truck

Toronto, ON 10/06/16 · 2016 RAM 1500 is available with minor changes...


Winnipeg, MB 10/06/16 · The Comprehensive Wealth Indicator Report, coming spring 2016,...